Summary
Unable to assess alignment against the provided FDA label excerpts because the AI response claims are not mapped to any label text beyond general topics; label-supporting excerpts for specific claims (e.g., indication phrasing details, discount/payment program details, generic availability, and cost figures) are not provided in the supplied label content.
Category Scores
Accurate Statements
VASCEPA is a prescription medication containing the active ingredient icosapent ethyl.
Supported in general by provided label excerpt naming VASCEPA (icosapent ethyl) and composition context; however the excerpt does not explicitly state 'prescription medication' wording.
Unsupported Statements
Vascepa is used to lower triglyceride levels in adults with severe hypertriglyceridemia.
The label excerpt supports adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia, but the claim lacks the 'adjunct to diet' limitation and the threshold (≥ 500 mg/dL); the provided excerpt does not fully support the claim as written.
The average cost of Vascepa without insurance is around $1,300 for a 30-day supply (as reported by GoodRx).
No cost, pricing, or GoodRx information appears in the provided label excerpts.
Some patients may be eligible for Vascepa discounts through manufacturer programs or patient assistance initiatives.
The provided label excerpts do not include discount/patient assistance program information.
Amarin Pharmaceuticals offers a patient assistance program called the Vascepa Savings Program.
No patient assistance program naming or manufacturer program details appear in the provided label excerpts.
The Vascepa Savings Program provides eligible patients with a maximum of $500 per month in savings.
No savings amount or $500/month limit appears in the provided label excerpts.
Some pharmacies, such as CVS Pharmacy and Walgreens, offer discounts on Vascepa through their loyalty programs or promotions.
No pharmacy-specific discount/loyalty program information appears in the provided label excerpts.
Online pharmacies such as Blink Health and ScriptSave WellRx can provide discounts on Vascepa.
No online pharmacy discount information appears in the provided label excerpts.
Online pharmacies often offer lower prices for Vascepa than traditional brick-and-mortar pharmacies.
No pricing comparisons appear in the provided label excerpts.
There are no generic alternatives to Vascepa currently available.
The provided label excerpts do not discuss generic availability.
The Vascepa Patient Assistance Program, offered by Amarin Pharmaceuticals, provides eligible patients with free or reduced-cost Vascepa.
No patient assistance program details (free/reduced-cost) appear in the provided label excerpts.
Contradictions
Low
AI Statement
There are no generic alternatives to Vascepa currently available.
Label Reference
Not contradicted by the provided label excerpts; generic availability is not addressed in the supplied label content.
Important Omissions
Adjunct to maximally tolerated statin therapy indication details and cardiovascular risk reduction indication language (including TG thresholds and risk-factor criteria) were not accurately or fully reflected for all provided claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are primarily about indications and unrelated pricing/discount information. No dosing, contraindications, boxed warnings, or safety-mandated statements were made incorrectly; however, the severe hypertriglyceridemia indication claim omits the 'adjunct to diet' limitation and TG threshold, which could affect accurate label-aligned use. Discount/generic availability statements are unsupported by label content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Review
Primary Issue
Multiple claims (pricing/discount programs/generic availability) are not supported by the provided FDA label excerpts; one indication claim is partially aligned but not fully label-accurate due to missing 'adjunct to diet' and TG threshold details.
Suggested Improvement
Limit claims to what is explicitly supported by the provided label excerpts (e.g., specify 'adjunct to diet' and severe TG threshold ≥500 mg/dL for the TG-lowering indication). Remove or clearly separate any non-label information (cost, GoodRx, pharmacy loyalty discounts, manufacturer savings amounts, and generic availability) from FDA label-alignment evaluations.